Elekta AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elekta AB (publ) is a Swedish medical technology company specializing in clinical solutions for treating cancer and brain disorders. Founded in 1972 and headquartered in Stockholm, Sweden, Elekta develops, manufactures, and sells advanced radiation therapy and radiosurgery equipment, oncology informatics, brachytherapy devices, neurosurgery tools, and particle therapy solutions. Its core product portfolio includes linear accelerators such as the Versa HD, Harmony, and the recently launched Evo CT-Linac, which features AI-enhanced adaptive imaging; the Elekta Unity MR-Linac that combines magnetic resonance imaging with radiation therapy; Gamma Knife systems including the latest Elekta Esprit; brachytherapy platforms with Flexitron afterloader and various applicators; as well as oncology software products like MOSAIQ oncology information system and Monaco treatment planning system. Geographically, Elekta operates globally across over 120 countries with major segments including the Americas, Europe, Middle East and Africa (EMEA), and Asia-Pacific (APAC). Key recent developments include the strategic acquisition of assets from its distributor in Croatia in 2025 to strengthen market presence and enhance regional cancer treatment capabilities. Elekta is also expanding partnerships, notably with RaySearch Laboratories and Radiology Oncology Systems, supporting AI-driven solutions and operational efficiencies under its ACCESS 2025 strategy aimed at cost savings and supply chain optimization. Recent product launches like the Evo AI-powered CT-Linac and software suite Elekta ONE Planning aim to advance treatment precision and improve profitability. Additionally, Elekta secured a significant USD 64 million order from Hospital Angeles Health System in Mexico for state-of-the-art linear accelerators and Gamma Knife equipment, with installations ongoing through 2027. Elekta's strategic focus remains on innovation in personalized radiation medicine, leveraging technology such as AI and online adaptive treatments to improve patient outcomes and access to advanced care globally. The company continues to strengthen its global footprint, pursue operational simplification, and maintain leadership in radiation oncology markets with a portfolio spanning hardware, software, and clinical service solutions designed for hospitals, cancer centers, and healthcare providers worldwide. Elekta employs approximately 4,700 staff and holds thousands of patents related to neurosurgical and radiation therapy technologies. Its strategic expansions, product innovations, and collaborations underline its commitment to advancing cancer and brain disorder treatments globally.
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
Elekta AB: Tricky, But With A Latent Upside
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Analyzing Anteris Technologies Global (NASDAQ:AVR) and Elekta (OTCMKTS:EKTAY)
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology
Elekta AB (publ) (EKTAY) Q2 2026 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q1 2026 Earnings Call Transcript
New Strong Sell Stocks for July 24th
Elekta AB: Latent Growth And A Recurring Base
Elekta AB (publ) (EKTAF) Q4 2025 Earnings Call Transcript
Should Value Investors Buy Elekta (EKTAY) Stock?
Elekta AB (publ) (EKTAF) Q3 2025 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q2 2025 Earnings Call Transcript
Are Investors Undervaluing Elekta (EKTAY) Right Now?
Is Elekta (EKTAY) Stock Undervalued Right Now?
Is Elekta (EKTAY) a Great Value Stock Right Now?
Should Value Investors Buy Elekta (EKTAY) Stock?
Elekta AB (publ) (EKTAF) Q1 2025 Earnings Call Transcript
Elekta AB (publ) (EKTAF) Q4 2024 Earnings Call Transcript